Cefminox sodium crystal form compound

A technology of cefminox sodium and compound, applied in the field of medicine, can solve the problems of local circulation disorder, blockage of blood supply, allergic reaction, etc., and achieves the effect that the number of insoluble particles changes little, is beneficial to use and operation, and shortens the dissolution time.

Active Publication Date: 2014-05-28
YOUCARE PHARMA GROUP +1
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Insoluble particles in intravenous infusion can cause harm to the human body. For example, larger insoluble particles can cause local circulation disorders and cause vascular embolism; too many particles can cause local

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cefminox sodium crystal form compound
  • Cefminox sodium crystal form compound
  • Cefminox sodium crystal form compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1, the preparation of cefminox sodium crystal form compound

[0043] 1) Preparation of solution A: Sterile filter 600L of mixed solvent A of ether and acetonitrile (the volume ratio of ether and acetonitrile is 5:1) into a crystallization tank, and cool down to 8°C for use, which is solution A;

[0044] 2) Preparation of solution B: at room temperature, add 60L of mixed solvent B of water and 1,4-dioxane (the volume ratio of water and 1,4-dioxane is 6:1) In the dissolution tank, add 30 kg of cefminox sodium crude product, add 0.45 kg of activated carbon after dissolving, stir for decolorization for 30 min, filter aseptically, wash with 10 kg of water for injection, collect filtrate and washing liquid, and obtain B solution;

[0045] 3) Add solution B to solution A, cool down to 12°C, keep the temperature, and stir at a stirring speed of 20 rpm for 25-35 minutes;

[0046] 4) Then lower the temperature to 2°C, control the stirring speed to 12 rpm, control the ...

Embodiment 2

[0049] Embodiment 2, the preparation of cefminox sodium crystal form compound

[0050] 1) Preparation of solution A: Sterile filter 600L of mixed solvent A of ether and acetonitrile (the volume ratio of ether and acetonitrile is 3:1) into a crystallization tank, cool down to 5°C and wait for use, which is solution A;

[0051] 2) Preparation of solution B: at room temperature, add 60L of mixed solvent B of water and 1,4-dioxane (the volume ratio of water and 1,4-dioxane is 5:1) In the dissolving tank, add 30 kg of cefminox sodium crude product, add 0.45 kg of activated carbon after dissolving, stir and decolorize for 25 min, filter aseptically, wash with 10 kg of water for injection, collect the filtrate and washing liquid, and obtain B solution;

[0052] 3) Add solution B to solution A, cool down to 10°C, keep the temperature, and stir at a stirring speed of 18 rpm for 25-35 minutes;

[0053] 4) Then lower the temperature to 0°C, control the stirring speed to 10 rpm, control ...

Embodiment 3

[0055] Embodiment 3, the preparation of cefminox sodium crystal form compound

[0056] 1) Prepare A solution: Sterile filter 600L of mixed solvent A of ether and acetonitrile (the volume ratio of ether and acetonitrile is 8:1) into a crystallization tank, cool down to 10°C and wait for use, which is A solution;

[0057] 2) Preparation of solution B: at room temperature, add 100L of mixed solvent B of water and 1,4-dioxane (where the volume ratio of water and 1,4-dioxane is 7:1) In the dissolving tank, add 30 kg of cefminox sodium crude product, add 0.45 kg of activated carbon after dissolving, stir and decolorize for 35 min, filter aseptically, wash with 10 kg of water for injection, collect filtrate and washing liquid, and obtain B solution;

[0058] 3) Add solution B to solution A, cool down to 15°C, keep the temperature, and stir at a stirring speed of 22 rpm for 25-35 minutes;

[0059] 4) Then lower the temperature to 5°C, control the stirring speed to 15 rpm, control the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a cefminox sodium crystal form compound. The structure formula of the cefminox sodium crystal form compound is shown as follows. The X-ray powder diffraction spectrum obtained by using Cu-K[alpha] ray of the cefminox sodium crystal form compound is shown as the figure 1. The cefminox sodium crystal form compound is a novel crystal form compound different from compounds in the prior art, and has better dissolution rate. Insoluble particles precipitated after the cefminox sodium crystal form compound is put for a long time are less than that of the compounds in the prior art. A cefminox sodium aseptic powder injection prepared from the cefminox sodium crystal form compound has good clinical effects for respiratory tract bacterial infection and bacteria curative effects, and has low occurrence rate of untoward effects.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a cefminox sodium crystal form compound and a preparation method thereof. Background technique [0002] Cefminox sodium is a third-generation cephalosporin, a derivative of cephamycin, which is made into sodium heptahydrate by a semi-synthetic method. It has good antibacterial effect on Gram-negative and positive bacteria. In particular, it has a strong antibacterial effect on Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus, and Bacteroides fragilis. It is stable to lactamase produced by various bacteria such as Escherichia coli, Proteus, and Bacteroides fragilis. Susceptible to streptococci (except enterococci). This product can hinder the formation of lipoproteins from peptidoglycan in the bacterial cell wall. The lipoprotein structure is unique to Gram-negative bacteria, so the effect on Gram-negative bacteria is stronger than other similar drugs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D501/57C07D501/12
CPCC07D501/12C07D501/57
Inventor 李琦杨磊
Owner YOUCARE PHARMA GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap